Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 46

1.

Molecular mechanisms of hypoxia in cancer.

Challapalli A, Carroll L, Aboagye EO.

Clin Transl Imaging. 2017;5(3):225-253. doi: 10.1007/s40336-017-0231-1. Epub 2017 May 11. Review.

2.

Activity of the novel polo-like kinase 4 inhibitor CFI-400945 in pancreatic cancer patient-derived xenografts.

Lohse I, Mason J, Cao PM, Pintilie M, Bray M, Hedley DW.

Oncotarget. 2017 Jan 10;8(2):3064-3071. doi: 10.18632/oncotarget.13619.

3.

Tissue metabolism and host-microbial interactions in the intestinal mucosa.

Chun C, Zheng L, Colgan SP.

Free Radic Biol Med. 2017 Apr;105:86-92. doi: 10.1016/j.freeradbiomed.2016.09.027. Epub 2016 Sep 28. Review.

4.

Targeting hypoxic microenvironment of pancreatic xenografts with the hypoxia-activated prodrug TH-302.

Lohse I, Rasowski J, Cao P, Pintilie M, Do T, Tsao MS, Hill RP, Hedley DW.

Oncotarget. 2016 Jun 7;7(23):33571-80. doi: 10.18632/oncotarget.9654.

5.

Breathless in the Gut: Implications of Luminal O2 for Microbial Pathogenicity.

Kelly CJ, Colgan SP.

Cell Host Microbe. 2016 Apr 13;19(4):427-8. doi: 10.1016/j.chom.2016.03.014.

6.

18F-EF5 PET Is Predictive of Response to Fractionated Radiotherapy in Preclinical Tumor Models.

Ali R, Apte S, Vilalta M, Subbarayan M, Miao Z, Chin FT, Graves EE.

PLoS One. 2015 Oct 2;10(10):e0139425. doi: 10.1371/journal.pone.0139425. eCollection 2015.

7.

BRCA1 and BRCA2 mutations sensitize to chemotherapy in patient-derived pancreatic cancer xenografts.

Lohse I, Borgida A, Cao P, Cheung M, Pintilie M, Bianco T, Holter S, Ibrahimov E, Kumareswaran R, Bristow RG, Tsao MS, Gallinger S, Hedley DW.

Br J Cancer. 2015 Jul 28;113(3):425-32. doi: 10.1038/bjc.2015.220. Epub 2015 Jul 16.

8.

Optimizing hypoxia detection and treatment strategies.

Koch CJ, Evans SM.

Semin Nucl Med. 2015 Mar;45(2):163-76. doi: 10.1053/j.semnuclmed.2014.10.004. Review.

9.

F-18 fluoromisonidazole for imaging tumor hypoxia: imaging the microenvironment for personalized cancer therapy.

Rajendran JG, Krohn KA.

Semin Nucl Med. 2015 Mar;45(2):151-62. doi: 10.1053/j.semnuclmed.2014.10.006. Review.

10.

Assessment of hypoxia in the stroma of patient-derived pancreatic tumor xenografts.

Lohse I, Lourenco C, Ibrahimov E, Pintilie M, Tsao MS, Hedley DW.

Cancers (Basel). 2014 Feb 26;6(1):459-71. doi: 10.3390/cancers6010459.

11.

Improved functionality of the vasculature during conventionally fractionated radiation therapy of prostate cancer.

Potiron VA, Abderrahmani R, Clément-Colmou K, Marionneau-Lambot S, Oullier T, Paris F, Supiot S.

PLoS One. 2013 Dec 31;8(12):e84076. doi: 10.1371/journal.pone.0084076. eCollection 2013.

12.

Imaging tumor hypoxia to advance radiation oncology.

Lee CT, Boss MK, Dewhirst MW.

Antioxid Redox Signal. 2014 Jul 10;21(2):313-37. doi: 10.1089/ars.2013.5759. Epub 2014 Mar 24. Review.

13.

Strategies To Assess Hypoxic/HIF-1-Active Cancer Cells for the Development of Innovative Radiation Therapy.

Yeom CJ, Zeng L, Zhu Y, Hiraoka M, Harada H.

Cancers (Basel). 2011 Sep 15;3(3):3610-31. doi: 10.3390/cancers3033610.

14.

Microenvironments and cellular characteristics in the micro tumor cords of malignant solid tumors.

Yeom CJ, Goto Y, Zhu Y, Hiraoka M, Harada H.

Int J Mol Sci. 2012 Oct 29;13(11):13949-65. doi: 10.3390/ijms131113949. Review.

15.

In vivo T cell activation in lymphoid tissues is inhibited in the oxygen-poor microenvironment.

Ohta A, Diwanji R, Kini R, Subramanian M, Ohta A, Sitkovsky M.

Front Immunol. 2011 Jul 5;2:27. doi: 10.3389/fimmu.2011.00027. eCollection 2011.

16.

Imaging hypoxia in gliomas.

Mendichovszky I, Jackson A.

Br J Radiol. 2011 Dec;84 Spec No 2:S145-58. doi: 10.1259/bjr/82292521. Review.

17.

Targeting hypoxic tumour cells to overcome metastasis.

Bennewith KL, Dedhar S.

BMC Cancer. 2011 Nov 30;11:504. doi: 10.1186/1471-2407-11-504. Review.

18.

Oxygen, a Key Factor Regulating Cell Behavior during Neurogenesis and Cerebral Diseases.

Zhang K, Zhu L, Fan M.

Front Mol Neurosci. 2011 Apr 4;4:5. doi: 10.3389/fnmol.2011.00005. eCollection 2011.

19.

Biodistribution and dosimetry of (18)F-EF5 in cancer patients with preliminary comparison of (18)F-EF5 uptake versus EF5 binding in human glioblastoma.

Koch CJ, Scheuermann JS, Divgi C, Judy KD, Kachur AV, Freifelder R, Reddin JS, Karp J, Stubbs JB, Hahn SM, Driesbaugh J, Smith D, Prendergast S, Evans SM.

Eur J Nucl Med Mol Imaging. 2010 Nov;37(11):2048-59. doi: 10.1007/s00259-010-1517-y. Epub 2010 Jun 29.

20.

Metronomic gemcitabine suppresses tumour growth, improves perfusion, and reduces hypoxia in human pancreatic ductal adenocarcinoma.

Cham KK, Baker JH, Takhar KS, Flexman JA, Wong MQ, Owen DA, Yung A, Kozlowski P, Reinsberg SA, Chu EM, Chang CW, Buczkowski AK, Chung SW, Scudamore CH, Minchinton AI, Yapp DT, Ng SS.

Br J Cancer. 2010 Jun 29;103(1):52-60. doi: 10.1038/sj.bjc.6605727. Epub 2010 Jun 8.

Supplemental Content

Support Center